false
0001711933
0001711933
2024-01-09
2024-01-09
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
January 9, 2024
Akoya
Biosciences, Inc.
(Exact name of registrant as specified in its
charter)
Delaware |
001-40344 |
47-5586242 |
(State or other jurisdiction
of incorporation) |
(Commission
File Number) |
(IRS Employer
Identification No.) |
100
Campus Drive, 6th Floor
Marlborough,
MA
(Address of principal executive offices) |
01752
(Zip Code) |
(855)
896-8401
(Registrant’s telephone number, including
area code)
Check the appropriate box below
if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
Title
of each class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
Common
stock, par value $0.00001 per share |
|
AKYA |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 9, 2024, Dr. Garry
Nolan, Ph.D., notified Akoya Biosciences, Inc. (the “Company”) of his resignation as a member of the Board of Directors
(the “Board”) of the Company, including all committees thereof, effective as of such date. Dr. Nolan’s resignation
was not the result of any dispute or disagreement with the Company or the Board on any matter relating to the operations, policies or
practices of the Company.
Item 7.01 Regulation FD.
On January 10,
2024, the Company issued a press release announcing the formation of a Scientific Advisory Board of the Company, which initially includes
Dr. James Allison, Dr. Padmanee Sharma and Dr. Nolan, with Dr. Nolan serving as Chair. A copy of the press release
is furnished as Exhibit 99.1 and is incorporated herein by reference.
The
information in Item 7.01 of this Current Report on Form 8-K, including the press release furnished as Exhibit 99.1 hereto, is
being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated
by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly
set forth by specific reference in such filing.
Item
9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: January 10, 2024 |
Akoya Biosciences, Inc. |
|
|
|
|
By: |
/s/ Brian McKelligon |
|
|
Brian McKelligon |
|
|
Chief Executive Officer |
Exhibit 99.1
Akoya Biosciences Announces that Garry Nolan, Ph.D., James Allison,
Ph.D., and Padmanee Sharma, M.D., Ph.D., Join Newly Created Scientific Advisory Board
Leading immunotherapy and immunobiology experts will offer strategic
direction and expertise in translational, clinical, and diagnostic applications of Akoya’s spatial biology solutions
MARLBOROUGH, Mass. (GLOBE NEWSWIRE) January 10, 2024 -- Akoya
Biosciences, Inc., (NASDAQ: AKYA), The Spatial Biology Company®, today announced the establishment of its Scientific
Advisory Board (SAB) to provide strategic guidance and consult on the Company's efforts to deliver spatial biology solutions for the
life sciences industry, from discovery to diagnostics.
The initial members of Akoya’s Scientific Advisory Board are:
| • | Garry Nolan, Ph.D., Rachford and Carlota A. Harris Professor in the Department of Pathology at Stanford University School of
Medicine, co-founder of Akoya Biosciences and inventor of the CODEX technology (now PhenoCycler) |
| • | James Allison, Ph.D., Regental Professor and Chair of the Department of Immunology, the Olga Keith Wiess Distinguished University
Chair for Cancer Research, and Director of the James P. Allison Institute at The University of Texas MD Anderson Cancer Center; recipient
of the 2018 Nobel Prize in Physiology or Medicine |
| • | Padmanee Sharma, M.D., Ph.D., Professor in the Departments of Genitourinary Medical Oncology and Immunology, Associate VP of
Immunobiology, the T.C. and Jeanette D. Hsu Endowed Chair in Cell Biology, and Director of Scientific Programs for the James P. Allison
Institute at MD Anderson |
"Our SAB includes leaders in immunotherapy, immunobiology and
innovation with deep knowledge and experience in translational research, the discovery of ground-breaking clinical therapies and the development
of disruptive and high impact technologies," said Brian McKelligon, Chief Executive Officer of Akoya Biosciences. "By bringing
together experts with unparalleled track records of success, the SAB will enable us to better serve customer needs, accelerate our leadership
position in spatial biology, and support Akoya’s mission to catalyze discovery and improve patient care."
Garry Nolan, Ph.D.
Professor Nolan will transition from
his role on the Akoya Board of Directors to Chair of the SAB. He co-founded Akoya Biosciences in 2015 and is the Rachford and Carlota
A. Harris Professor in the Department of Pathology at Stanford University School of Medicine. As a co-inventor of the CODEX technology,
Garry has focused his research efforts on developing novel technologies and computational methods for research into cancer, leukemia,
immunology, and autoimmune disease. Professor Nolan was the founder of a number of life sciences companies in addition to Akoya, including
Rigel Inc. (NASDAQ: RIGL), DVS Sciences (purchased by Fluidigm), Nodality, Inc., BINA (sold to Roche Diagnostics), Apprise (sold
to Roche Sequencing Solutions), Scale Bio (single cell ATAC, RNA, and protein), and serves as an advisor and board member for several
biotechnology companies. He has published over 350 research articles and is the holder of 50 US patents and has been honored as one of
the top 25 inventors at Stanford University. He trained with Leonard Herzenberg (for his Ph.D.) and Nobelist Dr. David Baltimore
for postdoctoral work. Professor Nolan is the first recipient of the Teal Innovator Award (2012) from the Department of Defense and has
been honored with a number of awards including Nature Publishing “Outstanding Research Achievement”, Stohlman Scholar from
the Leukemia and Lymphoma Society and Burroughs Wellcome Fund New Investigator Award.
James Allison, Ph.D.
Dr. Allison has spent a distinguished career studying the regulation
of T cell responses and developing strategies for cancer immunotherapy. He earned the 2018 Nobel Prize in Physiology or Medicine, which
he shared with Dr. Tasuku Honjo, "for their discovery of cancer therapy by inhibition of negative immune regulation." Among
his most notable discoveries are the determination of the T cell receptor structure and that CD28 is the major costimulatory molecule
that allows full activation of naïve T cells and prevents anergy in T cell clones. His lab resolved a major controversy by demonstrating
that CTLA-4 inhibits T-cell activation by opposing CD28-mediated costimulation and that blockade of CTLA-4 could enhance T cell responses,
leading to tumor rejection in animal models. This finding and a great deal of persistence paved the way for the field of immune checkpoint
blockade therapy for cancer. Work in his lab led to the development of ipilimumab, an antibody to human CTLA-4 and the first immune checkpoint
blockade therapy approved by the FDA. Among many honors, he is a member of the National Academies of Science and Medicine and received
the Lasker-Debakey Clinical Medical Research award in 2015. His current work seeks to improve immune checkpoint blockade therapies currently
used to identify new targets to unleash the immune system in order to eradicate cancer.
Padmanee
Sharma, M.D., Ph.D.
Dr. Sharma has written and conducted multiple innovative immunotherapy
clinical trials, with an emphasis on obtaining patients’ tumor samples for in-depth laboratory studies, including the first neoadjuvant
trial with immune checkpoint therapy and first clinical trial with immune checkpoint therapy for patients with bladder cancer. Her studies
have identified novel resistance mechanisms to immune checkpoint therapy, including loss of interferon (IFN) signaling, VISTA⁺ immunosuppressive
cells, increased EZH2 expression in T cells, TGFβ signaling in bone metastases, and CD73⁺ myeloid cells in GBM. These data
have led to initiation of new research studies focused on developing rational combination immunotherapy strategies for the treatment of
cancer patients. As a result of her outstanding contributions to the field of cancer immunotherapy, Dr. Sharma was selected as a
member of the American Society for Clinical Investigation (ASCI) and was awarded the Emil Frei III Award for Excellence in Translational
Research in 2016, the Coley Award for Distinguished Research for Tumor Immunology in 2018, the Women in Science with Excellence (WISE)
Award in 2020, the Heath Memorial Award in 2021 and the Randall Prize for Excellence in Cancer Research in 2021.
Disclosure
Dr. Allison and Dr. Sharma receive financial and equity compensation
as members of Akoya’s SAB, and these financial relationships have been disclosed to MD Anderson’s Conflict of Interest Committee
in accordance with institutional policy.
Forward-Looking Statements
This press release contains forward-looking statements that are based
on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release
other than statements of historical fact are forward-looking statements, including statements regarding our expectations about the potential
of our products and services, our ability to develop, commercialize and achieve market acceptance of our current and planned products
and services, our research and development efforts, our ability to execute on our plans and expectations, our future performance and other
matters regarding our business strategies and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words
“may,” “will,” “could,” “would,” “should,” “expect,” “intend,”
“plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,”
“potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology,
although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that
may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or
implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors,"
"Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file
with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination
of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking
statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof.
We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’
mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive
single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact
to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the
diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler®,
PhenoImager® Fusion and PhenoImager HT Instruments. To learn more about Akoya, visit www.akoyabio.com.
Akoya Biosciences Investor Contact
Priyam Shah
Sr. Director, Investor Relations
investors@akoyabio.com
Akoya Biosciences Media Contact:
Christine Quern
(617) 650-8497
media@akoyabio.com
v3.23.4
Cover
|
Jan. 09, 2024 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Jan. 09, 2024
|
Entity File Number |
001-40344
|
Entity Registrant Name |
Akoya
Biosciences, Inc.
|
Entity Central Index Key |
0001711933
|
Entity Tax Identification Number |
47-5586242
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
100
Campus Drive
|
Entity Address, Address Line Two |
6th Floor
|
Entity Address, City or Town |
Marlborough
|
Entity Address, State or Province |
MA
|
Entity Address, Postal Zip Code |
01752
|
City Area Code |
855
|
Local Phone Number |
896-8401
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common
stock, par value $0.00001 per share
|
Trading Symbol |
AKYA
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Akoya BioSciences (NASDAQ:AKYA)
過去 株価チャート
から 3 2024 まで 4 2024
Akoya BioSciences (NASDAQ:AKYA)
過去 株価チャート
から 4 2023 まで 4 2024